Robinson Chandler's Form 4 filing
Monopar TherapeuticsMNPR · filed Sep 26, 2025
- Accession no.
- 0001437749-25-029925
- Filed
- Sep 26, 2025, 3:53 PM ET
- Trade date
- Sep 24, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $35.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Robinson ChandlerCIK 0001727334 | Director, Officer (Chief Executive Officer) |
| Brown Michael JCIK 0001035909 | Other: Member of 10% Owner Group |
| Tactic Pharma LLCCIK 0001727357 | 10% Owner |
| Mazar Andrew PaulCIK 0001727393 | Other: Member of 10% Owner Group |
| O'Halloran Thomas V.CIK 0001727481 | Other: Member of 10% Owner Group |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 24, 2025 | Common Stock | SSaleDisposed | −550,229 | $63.61 | −$34,999,956.64 | 272,026 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.